Blockchain

Cartesi and Avail Announce Strategic Integration to Advance Web3 Development

New York, New York, July 2nd, 2024, Chainwire

Cartesi, a modular execution layer protocol that equips developers with access to a full Linux environment, and Avail, a modular blockchain framework designed to unify web3 and optimize data availability (DA) for scalable and customizable applications, are pleased to announce a close collaboration set to significantly advance web3 development.

This integration will offer a seamless and intuitive experience for developers by leveraging Cartesi’s RISC-V Linux-based execution capabilities and Avail’s reliable data availability solution, Avail DA. The user-friendly approach will simplify the complexities of decentralized application development, enabling faster and more efficient project deployment.

The modular stack allows both protocols to combine their unique properties, resulting in a robust protocol that is more powerful compared to monolithic stacks where all functionalities are integrated. In this sense, the Cartesi-Avail integration will enable developers to benefit from the increased computational power and flexible programming environment of the Cartesi stack, while also utilizing the enhanced data availability capabilities of Avail DA.

“By combining Cartesi’s cutting-edge RISC-V Linux-based execution with Avail DA, we are setting a new standard in the ease and efficiency of protocol development. This partnership empowers developers to overcome traditional barriers, accelerating innovation and the deployment of next-generation decentralized applications. We are thrilled to enable this leap forward in web3 development,” said Anurag Arjun, Co-Founder of Avail.

The collaboration between Cartesi and Avail marks a significant milestone in the web3 space. A dedicated data availability layer ensures critical transaction data remains available and verifiable while significantly reducing the costs associated with on-chain data availability. This makes dApps more affordable and accessible, while reliable data availability is crucial for the execution layer to perform transactions and execute contracts seamlessly. 

“The Cartesi-Avail integration brings into reality a powerful infrastructure for new possibilities and use cases in web3. This is exciting for us and a breath of fresh air for the industry,” said Erick de Moura, Co-Founder of Cartesi.

This partnership is expected to drive the creation of a more robust and versatile ecosystem, particularly benefiting gaming and DeFi verticals, empowering developers to experiment and innovate without being hindered by the limitations of current infrastructure.

Cartesi equips developers with access to a full Linux environment through its native virtual machine, and high-performance rollups designed to support next-generation dApps. By bridging the gap between traditional software and blockchain, Cartesi enables developers to create more sophisticated and scalable dApps with ease. Avail DA offers secure data availability guarantees for entire networks of blockchains, enabling them to scale efficiently and in an unlimited capacity. Using validity proofs with data availability sampling provides robust security and enhanced scalability for blockchain applications. 

About Cartesi: 

Cartesi is a powerful modular blockchain protocol that supercharges the web3 space. Cartesi equips developers with access to a full Linux environment through its native virtual machine, and high-performance rollups designed to support next-generation dApps. To learn more about Cartesi, users can visit https://cartesi.io/

About Avail:

Avail is led by Polygon’s former co-founder Anurag Arjun and is building a unification layer to solve rollup fragmentation at scale. Avail addresses this from first principles solving blockchain scalability with Avail DA, a foundational DA layer which implements the same technology planned for Ethereum’s danksharding roadmap, including KZG Commitments and Data Availability Sampling (DAS). Avail Nexus addresses growing fragmentation concerns with permissionless interoperability, leveraging proof aggregation on Avail’s scalable DA layer. Avail’s security is then reinforced with multi-asset staking through Avail Fusion.

availproject.org

Users can learn more about Avail on Discord, Twitter, GitHub, Our Blog

Contact

PR Manager
Lindsay Strebel
Blokhaus Inc.
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Equasens: 2024 half-year results

2024-09-27T16:00:00Z

Villers-lès-Nancy, 27 September 2024 - 6:00 p.m. (CET)

PRESS RELEASE

2024 half-year results

  • Group results impacted by weaker economic conditions and continuing investment efforts in H1:
    • Revenue: €108.0m, -4.1%
    • Current Operating Income: €20.9m, -24.1%
  • Net Profit attributable to the Group: €17.2m, -21.8%
  • Though with a profit margin that continues to be very positive:
    • Ratio of Current Operating Income (COI) to Sales: 19.3% on a reported basis and 20.0% like-for-like
H1 RESULTS (€M)2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Revenue112.6108.0-4.6-4.1%-3.7-8.3-7.4%
Current operating income (COI)27.520.9-6.6-24.1%0.0-6.7-24.3%
Net Profit22.918.1-4.8-21.0%0.0-4.8-21.1%
Net Profit attributable to the Group22.017.2-4.8-21.8%   

The financial statements for the six-month period ended 30 June 2024 were reviewed and adopted by EQUASENS' Board of Directors, chaired by Thierry Chapusot, on 27 September 2024. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.

_____

Results at 30 June 2024

H1 Current Operating Income / Division2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Pharmagest18.414.1-4.3-23.5%-0.1-4.4-24.0%
Axigate Link4.64.4-0.2-4.9% -0.2-4.9%
e-Connect3.62.5-1.1-29.9% -1.1-29.9%
Medical Solutions1.30.0-1.3-100.0%0.1-1.2-92.5%
Fintech-0.4-0.10.369.3% 0.3-69.3%
Current Operating Income27.520.9-6.6-24.1%0.0-6.7-24.3%
  • PHARMAGEST division: a contraction in earnings reflecting lower sales and reinforced teams in Europe (COI/Sales: 17.2%)

The decline in the Division's operating income is mainly attributable to a reduction in sales in France in the configuration and hardware segment. In a persistently challenging economic environment, the Division continued to focus its commercial strategy on acquiring new customers and regularly rolling out new software and hardware solutions.
Despite this, recurring revenues were bolstered by the combined contribution of new SaaS offerings and contract indexation.
To accelerate the deployment of solutions in Europe, the R&D and sales teams continued to be strengthened.

  • AXIGATE LINK division: the profit margin remains high (COI/Sales: 28.6%)

Strategic investments to support the roll-out of SaaS solutions such as TitanLink for Nursing Homes in Europe, and the extension of homecare services, have temporarily weighed on the Division's results.

  • E-CONNECT division: current operating income declined in response to lower sales (COI/Sales: 45.4%)

As previously reported, H1 2023 sales and earnings were boosted by the announced discontinuation of sales of Application Reader Terminals.
The downturn in business in the first half of 2024 thus reflected the corresponding decline in sales.
Despite this unfavourable environment, the Division demonstrated its ability to adapt by maintaining a healthy profit margin based on tight cost controls.

  • MEDICAL SOLUTIONS division: a year of transition between the Ségur digital healthcare investment programme and a new software solution (COI/Sales: -)

Preparations for the Division's future involving the development of a new software platform and optimising the sales organisation led to significant investments which, in conjunction with lower sales following the end of the Ségur programme roll-out, weighed on the Division's results. Recurring revenues rose 13.7%, resulting in a gross margin of 72.8%.

  • FINTECH division: efforts to stabilise the business paid off in H1, with an improvement in earnings of €0.3m (COI/Sales: -)

Consolidated balance sheet highlights

  • Cash flow after interest and tax maintained a positive trend at €20.8m.
  • Financial investments, through acquisitions as well as capital expenditures, in particular for the EQUASENS private healthcare cloud, continued, with more than €16.0m committed in H1.
  • The net financial surplus at 30/06/2024 of €87.9m takes into account a change in presentation of IFRS 16 lease liabilities and put options for minority shareholders of €10.8m (recognised under other liabilities versus financial liabilities previously).

2024 outlook

  • The Group maintains its forecast for a return to revenue growth starting in the second half of 2024, and an acceleration in 2025 driven by current investments and an economic climate that looks set to improve, particularly for pharmacies in France.
  • The Group will continue to invest in R&D, infrastructure and sales forces in France and Europe in the second half of 2024. And while this will have a temporary impact on profitability in 2024, it should generate a return on investment from 2025 onwards.
  • With a strategy focused on patients and interoperability, the Group is ideally positioned to seize opportunities for external growth in France and Europe.

Financial calendar:

  • 1 October 2024: Presentation of H1 2024 results
  • 7 November 2024: Publication of Q3 2024 revenue
  • 6 February 2025: Publication of f Q4/FY 2024 revenue

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - [email protected]

Financial communication agency:
FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - [email protected]

Attachment


GlobeNewsWire News

Recent Comments